 Lee Newman
Concepts (512)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Occupational Health | 28 | 2022 | 172 | 13.080 |
Why?
| | Small Business | 14 | 2022 | 51 | 8.160 |
Why?
| | Saccharum | 14 | 2023 | 84 | 7.010 |
Why?
| | Berylliosis | 36 | 2018 | 183 | 6.190 |
Why?
| | Occupational Exposure | 30 | 2023 | 277 | 6.120 |
Why?
| | Farmers | 10 | 2022 | 61 | 5.900 |
Why?
| | Beryllium | 30 | 2018 | 151 | 5.180 |
Why?
| | Renal Insufficiency, Chronic | 12 | 2023 | 589 | 4.270 |
Why?
| | Occupational Injuries | 7 | 2023 | 50 | 4.020 |
Why?
| | Workplace | 25 | 2023 | 222 | 4.010 |
Why?
| | Agricultural Workers' Diseases | 5 | 2020 | 32 | 2.950 |
Why?
| | Health Promotion | 11 | 2021 | 691 | 2.810 |
Why?
| | Occupational Diseases | 9 | 2019 | 136 | 2.640 |
Why?
| | Heat Stress Disorders | 5 | 2023 | 61 | 2.530 |
Why?
| | Agriculture | 6 | 2020 | 90 | 2.410 |
Why?
| | Workers' Compensation | 4 | 2019 | 28 | 2.070 |
Why?
| | Hot Temperature | 7 | 2023 | 334 | 1.930 |
Why?
| | Organizational Culture | 5 | 2022 | 121 | 1.770 |
Why?
| | Guatemala | 12 | 2021 | 296 | 1.730 |
Why?
| | Leadership | 6 | 2022 | 311 | 1.730 |
Why?
| | Sarcoidosis | 13 | 2012 | 130 | 1.620 |
Why?
| | Safety Management | 6 | 2021 | 109 | 1.530 |
Why?
| | Glomerular Filtration Rate | 5 | 2021 | 683 | 1.510 |
Why?
| | Kidney | 6 | 2021 | 1353 | 1.310 |
Why?
| | Creatinine | 6 | 2023 | 491 | 1.280 |
Why?
| | Humans | 131 | 2023 | 118974 | 1.270 |
Why?
| | Absenteeism | 2 | 2018 | 38 | 1.230 |
Why?
| | Lymphocytes | 4 | 2018 | 347 | 1.170 |
Why?
| | Adult | 56 | 2021 | 31512 | 1.160 |
Why?
| | Health Behavior | 5 | 2022 | 720 | 1.150 |
Why?
| | Chronic Disease | 25 | 2018 | 1636 | 1.150 |
Why?
| | Colorado | 19 | 2023 | 4196 | 1.030 |
Why?
| | Industry | 4 | 2019 | 69 | 0.980 |
Why?
| | Male | 68 | 2023 | 57801 | 0.980 |
Why?
| | Dehydration | 3 | 2020 | 61 | 0.920 |
Why?
| | Occupational Stress | 1 | 2023 | 34 | 0.890 |
Why?
| | Environmental Monitoring | 5 | 2022 | 296 | 0.880 |
Why?
| | Air Pollutants | 4 | 2020 | 316 | 0.880 |
Why?
| | Point-of-Care Testing | 2 | 2023 | 31 | 0.870 |
Why?
| | Longitudinal Studies | 10 | 2021 | 2513 | 0.840 |
Why?
| | Middle Aged | 50 | 2021 | 27617 | 0.830 |
Why?
| | Acute Kidney Injury | 2 | 2019 | 709 | 0.810 |
Why?
| | Analgesics, Opioid | 2 | 2018 | 794 | 0.780 |
Why?
| | Efficiency | 2 | 2018 | 89 | 0.780 |
Why?
| | Arsenic | 1 | 2021 | 40 | 0.770 |
Why?
| | Anemia | 1 | 2021 | 146 | 0.740 |
Why?
| | Neurophysins | 1 | 2020 | 7 | 0.740 |
Why?
| | Risk Factors | 23 | 2021 | 9000 | 0.740 |
Why?
| | Capacity Building | 1 | 2020 | 51 | 0.730 |
Why?
| | Cross-Sectional Studies | 12 | 2021 | 4552 | 0.730 |
Why?
| | Inhalation Exposure | 1 | 2020 | 87 | 0.720 |
Why?
| | Tobacco Smoke Pollution | 2 | 2021 | 233 | 0.720 |
Why?
| | Vasopressins | 1 | 2020 | 64 | 0.710 |
Why?
| | HLA-DP Antigens | 6 | 2011 | 33 | 0.710 |
Why?
| | Glycopeptides | 1 | 2020 | 58 | 0.710 |
Why?
| | Respiratory Hypersensitivity | 4 | 2004 | 65 | 0.710 |
Why?
| | Sleep | 2 | 2023 | 660 | 0.700 |
Why?
| | Biomarkers | 6 | 2020 | 3588 | 0.700 |
Why?
| | Protein Precursors | 1 | 2020 | 126 | 0.690 |
Why?
| | Presenteeism | 1 | 2018 | 5 | 0.670 |
Why?
| | Veterinarians | 1 | 2018 | 11 | 0.660 |
Why?
| | Cell Proliferation | 5 | 2018 | 2275 | 0.660 |
Why?
| | Female | 57 | 2021 | 61565 | 0.640 |
Why?
| | Smoking | 8 | 2021 | 1487 | 0.640 |
Why?
| | Accidents, Occupational | 2 | 2015 | 14 | 0.630 |
Why?
| | Young Adult | 13 | 2021 | 10793 | 0.630 |
Why?
| | Drug Utilization | 1 | 2018 | 169 | 0.620 |
Why?
| | Text Messaging | 1 | 2020 | 155 | 0.620 |
Why?
| | Body Composition | 1 | 2021 | 653 | 0.610 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 89 | 0.600 |
Why?
| | Extraction and Processing Industry | 2 | 2014 | 11 | 0.600 |
Why?
| | CD4-Positive T-Lymphocytes | 12 | 2011 | 984 | 0.600 |
Why?
| | Work Performance | 1 | 2017 | 6 | 0.600 |
Why?
| | Metabolic Diseases | 1 | 2018 | 103 | 0.600 |
Why?
| | Professional Role | 1 | 2018 | 153 | 0.590 |
Why?
| | Environmental Exposure | 8 | 2013 | 405 | 0.590 |
Why?
| | Guidelines as Topic | 1 | 2018 | 262 | 0.580 |
Why?
| | Renal Insufficiency | 1 | 2018 | 150 | 0.570 |
Why?
| | Health Policy | 1 | 2019 | 333 | 0.560 |
Why?
| | Sarcoidosis, Pulmonary | 8 | 2010 | 56 | 0.560 |
Why?
| | Lymphocyte Activation | 16 | 2014 | 1067 | 0.560 |
Why?
| | Federal Government | 1 | 2016 | 26 | 0.560 |
Why?
| | Mass Screening | 3 | 2022 | 1052 | 0.550 |
Why?
| | CpG Islands | 1 | 2015 | 119 | 0.540 |
Why?
| | Food Industry | 1 | 2015 | 14 | 0.530 |
Why?
| | Antigens, Bacterial | 4 | 2012 | 116 | 0.530 |
Why?
| | Safety | 2 | 2015 | 304 | 0.530 |
Why?
| | Chronic Pain | 1 | 2018 | 211 | 0.520 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2015 | 1171 | 0.510 |
Why?
| | Occupational Health Services | 1 | 2014 | 31 | 0.490 |
Why?
| | Guideline Adherence | 1 | 2018 | 523 | 0.490 |
Why?
| | United States | 16 | 2022 | 12555 | 0.480 |
Why?
| | Oil and Gas Fields | 1 | 2014 | 32 | 0.470 |
Why?
| | Population Surveillance | 3 | 2018 | 413 | 0.460 |
Why?
| | Lung | 11 | 2019 | 3664 | 0.460 |
Why?
| | Granuloma, Respiratory Tract | 4 | 2007 | 12 | 0.460 |
Why?
| | Natural Gas | 4 | 2014 | 30 | 0.450 |
Why?
| | Life Style | 1 | 2015 | 430 | 0.430 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 199 | 0.430 |
Why?
| | Aged | 22 | 2021 | 19657 | 0.420 |
Why?
| | Latin America | 2 | 2022 | 74 | 0.410 |
Why?
| | Mycobacterium | 3 | 2009 | 103 | 0.400 |
Why?
| | DNA Methylation | 1 | 2015 | 503 | 0.400 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 417 | 0.400 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 554 | 0.400 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1158 | 0.390 |
Why?
| | Hypertension | 1 | 2020 | 1203 | 0.390 |
Why?
| | Mass Spectrometry | 1 | 2014 | 681 | 0.380 |
Why?
| | Air Pollution, Indoor | 3 | 2019 | 117 | 0.380 |
Why?
| | Logistic Models | 7 | 2022 | 1901 | 0.380 |
Why?
| | Mycobacterium Infections | 2 | 2012 | 61 | 0.380 |
Why?
| | HLA-DP beta-Chains | 7 | 2014 | 78 | 0.370 |
Why?
| | Macrophages | 2 | 2015 | 1324 | 0.370 |
Why?
| | Ferritins | 2 | 2014 | 61 | 0.370 |
Why?
| | Mental Disorders | 1 | 2018 | 939 | 0.370 |
Why?
| | Macrophages, Alveolar | 2 | 2004 | 359 | 0.370 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1200 | 0.360 |
Why?
| | Electrolytes | 2 | 2020 | 59 | 0.360 |
Why?
| | Prevalence | 3 | 2021 | 2326 | 0.360 |
Why?
| | Health Status | 3 | 2021 | 726 | 0.340 |
Why?
| | B-Lymphocytes | 1 | 2014 | 770 | 0.340 |
Why?
| | Perception | 3 | 2021 | 314 | 0.340 |
Why?
| | Temperature | 2 | 2023 | 622 | 0.340 |
Why?
| | HLA Antigens | 4 | 2010 | 230 | 0.330 |
Why?
| | Delivery of Health Care | 1 | 2016 | 867 | 0.330 |
Why?
| | Pulmonary Fibrosis | 2 | 2005 | 303 | 0.330 |
Why?
| | Data Collection | 1 | 2011 | 658 | 0.330 |
Why?
| | T-Lymphocytes | 3 | 2014 | 1774 | 0.330 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1474 | 0.320 |
Why?
| | HLA-DR Antigens | 7 | 2010 | 224 | 0.320 |
Why?
| | Insurance Claim Reporting | 2 | 2018 | 24 | 0.310 |
Why?
| | Police | 1 | 2007 | 34 | 0.310 |
Why?
| | Program Development | 2 | 2020 | 357 | 0.300 |
Why?
| | Methamphetamine | 1 | 2007 | 51 | 0.300 |
Why?
| | Respiratory Protective Devices | 2 | 2007 | 13 | 0.300 |
Why?
| | Immunization | 3 | 2005 | 412 | 0.300 |
Why?
| | Internet | 1 | 2011 | 633 | 0.300 |
Why?
| | Genetic Predisposition to Disease | 8 | 2010 | 2275 | 0.300 |
Why?
| | Wyoming | 2 | 2018 | 17 | 0.290 |
Why?
| | Sensitivity and Specificity | 7 | 2023 | 1795 | 0.290 |
Why?
| | Prospective Studies | 5 | 2020 | 6471 | 0.290 |
Why?
| | Case-Control Studies | 10 | 2018 | 3171 | 0.290 |
Why?
| | Central Nervous System Stimulants | 1 | 2007 | 142 | 0.280 |
Why?
| | Pilot Projects | 2 | 2021 | 1419 | 0.280 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 2005 | 2 | 0.280 |
Why?
| | Apoptosis | 4 | 2005 | 2484 | 0.280 |
Why?
| | Plutonium | 1 | 2005 | 2 | 0.270 |
Why?
| | Neopterin | 2 | 2003 | 8 | 0.270 |
Why?
| | Proteomics | 2 | 2011 | 876 | 0.270 |
Why?
| | Influenza, Human | 1 | 2011 | 554 | 0.270 |
Why?
| | Cohort Studies | 6 | 2019 | 5116 | 0.270 |
Why?
| | Chemical Industry | 1 | 2005 | 9 | 0.270 |
Why?
| | Antigen Presentation | 4 | 2014 | 194 | 0.260 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2006 | 79 | 0.260 |
Why?
| | Bronchoalveolar Lavage Fluid | 8 | 2009 | 613 | 0.260 |
Why?
| | Research | 3 | 2018 | 411 | 0.260 |
Why?
| | Nuclear Warfare | 1 | 2004 | 7 | 0.250 |
Why?
| | Particulate Matter | 2 | 2020 | 244 | 0.250 |
Why?
| | Electronic Health Records | 1 | 2011 | 829 | 0.250 |
Why?
| | Pandemics | 3 | 2022 | 1355 | 0.250 |
Why?
| | Cadmium | 2 | 2022 | 62 | 0.250 |
Why?
| | Age of Onset | 1 | 2006 | 467 | 0.240 |
Why?
| | Research Design | 2 | 2022 | 969 | 0.240 |
Why?
| | Residence Characteristics | 2 | 2018 | 299 | 0.230 |
Why?
| | Risk Assessment | 5 | 2021 | 3057 | 0.230 |
Why?
| | Vaccination | 1 | 2011 | 1222 | 0.230 |
Why?
| | Pneumoconiosis | 2 | 2004 | 12 | 0.230 |
Why?
| | Climate Change | 2 | 2022 | 150 | 0.220 |
Why?
| | Volcanic Eruptions | 1 | 2022 | 7 | 0.220 |
Why?
| | Ventilation | 2 | 2019 | 33 | 0.220 |
Why?
| | Prognosis | 5 | 2020 | 3443 | 0.220 |
Why?
| | Inflammation Mediators | 3 | 2014 | 502 | 0.220 |
Why?
| | Metals, Heavy | 1 | 2022 | 22 | 0.220 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 526 | 0.210 |
Why?
| | Immunity, Active | 1 | 2002 | 10 | 0.210 |
Why?
| | Metals | 2 | 2004 | 111 | 0.210 |
Why?
| | Health Surveys | 2 | 2018 | 454 | 0.210 |
Why?
| | Crops, Agricultural | 2 | 2019 | 35 | 0.210 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 355 | 0.210 |
Why?
| | Respiratory Tract Infections | 1 | 2006 | 331 | 0.210 |
Why?
| | Models, Immunological | 1 | 2002 | 94 | 0.200 |
Why?
| | Calculi | 1 | 2021 | 14 | 0.200 |
Why?
| | Aged, 80 and over | 8 | 2011 | 6561 | 0.200 |
Why?
| | Cotinine | 1 | 2021 | 76 | 0.200 |
Why?
| | Organizational Innovation | 1 | 2022 | 138 | 0.200 |
Why?
| | Nickel | 1 | 2021 | 53 | 0.190 |
Why?
| | Beverages | 1 | 2020 | 70 | 0.190 |
Why?
| | Time Factors | 4 | 2019 | 6412 | 0.190 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1323 | 0.190 |
Why?
| | Policy | 1 | 2021 | 133 | 0.180 |
Why?
| | Noise, Occupational | 1 | 2019 | 5 | 0.180 |
Why?
| | HLA-DQ Antigens | 4 | 2010 | 176 | 0.180 |
Why?
| | Sri Lanka | 1 | 2019 | 12 | 0.180 |
Why?
| | Kidney Function Tests | 1 | 2020 | 164 | 0.180 |
Why?
| | Specific Gravity | 1 | 2019 | 13 | 0.180 |
Why?
| | Social Support | 1 | 2023 | 542 | 0.170 |
Why?
| | Hemoglobins | 1 | 2021 | 326 | 0.170 |
Why?
| | Central America | 1 | 2019 | 27 | 0.170 |
Why?
| | Global Health | 2 | 2016 | 310 | 0.170 |
Why?
| | Lung Diseases, Interstitial | 1 | 2004 | 464 | 0.170 |
Why?
| | Nutritional Status | 1 | 2021 | 300 | 0.170 |
Why?
| | Adolescent | 7 | 2021 | 18480 | 0.170 |
Why?
| | Heat-Shock Response | 1 | 2019 | 59 | 0.170 |
Why?
| | India | 1 | 2019 | 141 | 0.170 |
Why?
| | Body Mass Index | 2 | 2018 | 2092 | 0.170 |
Why?
| | Blood Proteins | 2 | 2011 | 248 | 0.170 |
Why?
| | Climate | 1 | 2019 | 91 | 0.170 |
Why?
| | Headache Disorders | 1 | 2018 | 12 | 0.170 |
Why?
| | Unemployment | 1 | 2018 | 42 | 0.170 |
Why?
| | Work Capacity Evaluation | 1 | 2018 | 13 | 0.170 |
Why?
| | Survivorship | 1 | 2018 | 38 | 0.170 |
Why?
| | Musculoskeletal Pain | 1 | 2018 | 22 | 0.160 |
Why?
| | Interferon-gamma | 5 | 2015 | 736 | 0.160 |
Why?
| | False Positive Reactions | 1 | 2018 | 115 | 0.160 |
Why?
| | Digestive System Diseases | 1 | 2018 | 27 | 0.160 |
Why?
| | Neoplasms | 3 | 2018 | 2179 | 0.160 |
Why?
| | Urologic Diseases | 1 | 2018 | 36 | 0.160 |
Why?
| | Asbestosis | 2 | 2011 | 13 | 0.160 |
Why?
| | Granuloma | 2 | 2014 | 87 | 0.160 |
Why?
| | Models, Psychological | 1 | 2020 | 298 | 0.160 |
Why?
| | Job Satisfaction | 1 | 2020 | 175 | 0.160 |
Why?
| | Educational Status | 1 | 2020 | 437 | 0.160 |
Why?
| | Reference Standards | 1 | 2018 | 176 | 0.160 |
Why?
| | Benchmarking | 1 | 2019 | 172 | 0.160 |
Why?
| | Catalase | 2 | 2009 | 123 | 0.160 |
Why?
| | Adaptation, Physiological | 1 | 2022 | 502 | 0.160 |
Why?
| | Fever | 1 | 2019 | 283 | 0.160 |
Why?
| | Awareness | 1 | 2018 | 93 | 0.160 |
Why?
| | Cytokines | 3 | 2014 | 1900 | 0.160 |
Why?
| | Self Report | 1 | 2021 | 699 | 0.150 |
Why?
| | Physical Exertion | 1 | 2019 | 222 | 0.150 |
Why?
| | Epidemics | 1 | 2018 | 70 | 0.150 |
Why?
| | Arthritis | 1 | 2018 | 112 | 0.150 |
Why?
| | Employment | 1 | 2018 | 135 | 0.150 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1284 | 0.150 |
Why?
| | Air Pollutants, Occupational | 3 | 2007 | 33 | 0.150 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 1137 | 0.150 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 143 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2018 | 248 | 0.140 |
Why?
| | Nuclear Energy | 1 | 2016 | 2 | 0.140 |
Why?
| | Nuclear Power Plants | 1 | 2016 | 2 | 0.140 |
Why?
| | Mice | 8 | 2019 | 15520 | 0.140 |
Why?
| | Community Health Planning | 1 | 2016 | 44 | 0.140 |
Why?
| | HLA-DRB1 Chains | 6 | 2010 | 97 | 0.140 |
Why?
| | Diagnosis, Differential | 4 | 2004 | 1384 | 0.140 |
Why?
| | Public-Private Sector Partnerships | 1 | 2016 | 43 | 0.140 |
Why?
| | Immunity, Innate | 1 | 2002 | 745 | 0.140 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1125 | 0.140 |
Why?
| | Motivation | 1 | 2020 | 506 | 0.140 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1996 | 91 | 0.130 |
Why?
| | Population Health | 1 | 2016 | 46 | 0.130 |
Why?
| | Cell Line, Transformed | 2 | 2014 | 136 | 0.130 |
Why?
| | Recurrence | 1 | 2018 | 975 | 0.130 |
Why?
| | Linear Models | 1 | 2018 | 827 | 0.130 |
Why?
| | Hypersensitivity | 2 | 2012 | 268 | 0.130 |
Why?
| | Cell Line | 2 | 2015 | 2707 | 0.130 |
Why?
| | Mast Cells | 1 | 1996 | 115 | 0.130 |
Why?
| | Medical Laboratory Personnel | 2 | 2006 | 8 | 0.130 |
Why?
| | Radiography, Thoracic | 4 | 2006 | 164 | 0.130 |
Why?
| | Kidney Diseases | 1 | 2019 | 439 | 0.130 |
Why?
| | Heart Diseases | 1 | 2018 | 341 | 0.130 |
Why?
| | Cancer Survivors | 1 | 2018 | 201 | 0.130 |
Why?
| | Macrophage Activation | 1 | 2015 | 168 | 0.130 |
Why?
| | Disease Progression | 5 | 2011 | 2490 | 0.120 |
Why?
| | Retrospective Studies | 4 | 2020 | 12978 | 0.120 |
Why?
| | Communication | 1 | 2020 | 761 | 0.120 |
Why?
| | Community Health Services | 1 | 2016 | 212 | 0.120 |
Why?
| | Ions | 1 | 2014 | 62 | 0.120 |
Why?
| | Program Evaluation | 1 | 2018 | 845 | 0.120 |
Why?
| | Research Personnel | 1 | 2016 | 158 | 0.120 |
Why?
| | Fruit | 1 | 2015 | 130 | 0.120 |
Why?
| | Vegetables | 1 | 2015 | 133 | 0.120 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2011 | 146 | 0.120 |
Why?
| | Endotoxins | 2 | 2006 | 234 | 0.120 |
Why?
| | Health Impact Assessment | 1 | 2013 | 8 | 0.120 |
Why?
| | Allergens | 3 | 2006 | 424 | 0.120 |
Why?
| | Incidence | 2 | 2018 | 2424 | 0.110 |
Why?
| | Models, Biological | 1 | 2021 | 1715 | 0.110 |
Why?
| | Sex Factors | 1 | 2018 | 1781 | 0.110 |
Why?
| | Genotype | 6 | 2011 | 1882 | 0.110 |
Why?
| | Water Supply | 2 | 2016 | 71 | 0.110 |
Why?
| | Diabetes Mellitus | 1 | 2021 | 942 | 0.110 |
Why?
| | Immunologic Memory | 2 | 2005 | 313 | 0.110 |
Why?
| | Maximum Allowable Concentration | 2 | 2019 | 14 | 0.110 |
Why?
| | Antigens, Fungal | 1 | 2012 | 26 | 0.110 |
Why?
| | Bacterial Proteins | 2 | 2009 | 759 | 0.110 |
Why?
| | Cell Division | 2 | 2004 | 776 | 0.110 |
Why?
| | Paper | 1 | 2011 | 9 | 0.110 |
Why?
| | Hydrocarbons | 1 | 2012 | 34 | 0.110 |
Why?
| | Up-Regulation | 2 | 2006 | 872 | 0.100 |
Why?
| | Personnel, Hospital | 1 | 2011 | 23 | 0.100 |
Why?
| | Vital Capacity | 2 | 2019 | 260 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 2 | 2005 | 396 | 0.100 |
Why?
| | Pulmonary Gas Exchange | 2 | 2004 | 117 | 0.100 |
Why?
| | Health Services Research | 1 | 2014 | 385 | 0.100 |
Why?
| | Glutamic Acid | 2 | 2003 | 224 | 0.100 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1440 | 0.100 |
Why?
| | Schools, Veterinary | 1 | 2010 | 2 | 0.100 |
Why?
| | Alleles | 4 | 2011 | 832 | 0.100 |
Why?
| | Forced Expiratory Volume | 2 | 2019 | 520 | 0.100 |
Why?
| | Genes, MHC Class II | 1 | 2010 | 72 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2445 | 0.090 |
Why?
| | Phenotype | 3 | 2010 | 3003 | 0.090 |
Why?
| | Sulfasalazine | 1 | 2009 | 21 | 0.090 |
Why?
| | Mesalamine | 1 | 2009 | 8 | 0.090 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 971 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 304 | 0.090 |
Why?
| | Uveitis | 1 | 2010 | 116 | 0.090 |
Why?
| | Air Pollution | 1 | 2012 | 209 | 0.090 |
Why?
| | Cell Separation | 2 | 2009 | 296 | 0.090 |
Why?
| | Silicosis | 1 | 1989 | 21 | 0.090 |
Why?
| | Animals | 9 | 2019 | 33381 | 0.080 |
Why?
| | Alcohol Drinking | 1 | 2015 | 652 | 0.080 |
Why?
| | Latent Tuberculosis | 1 | 2009 | 69 | 0.080 |
Why?
| | Swimming Pools | 1 | 2007 | 6 | 0.080 |
Why?
| | Hydrotherapy | 1 | 2007 | 8 | 0.080 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2004 | 632 | 0.080 |
Why?
| | Crime | 1 | 2007 | 60 | 0.080 |
Why?
| | RNA, Messenger | 2 | 2006 | 2657 | 0.080 |
Why?
| | Animal Technicians | 2 | 2006 | 3 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2436 | 0.080 |
Why?
| | Severity of Illness Index | 4 | 2007 | 2674 | 0.080 |
Why?
| | Spirometry | 3 | 2019 | 263 | 0.080 |
Why?
| | Water Microbiology | 1 | 2007 | 78 | 0.070 |
Why?
| | Influenza Vaccines | 1 | 2011 | 500 | 0.070 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2007 | 164 | 0.070 |
Why?
| | Transcription Factor AP-1 | 1 | 2006 | 81 | 0.070 |
Why?
| | Cells, Cultured | 5 | 2009 | 4077 | 0.070 |
Why?
| | Reactive Oxygen Species | 2 | 2008 | 576 | 0.070 |
Why?
| | Genetic Markers | 2 | 2010 | 348 | 0.070 |
Why?
| | Aerosols | 1 | 2007 | 221 | 0.070 |
Why?
| | Gene Dosage | 1 | 2006 | 136 | 0.070 |
Why?
| | RNA Precursors | 1 | 2006 | 136 | 0.070 |
Why?
| | Risk | 2 | 2007 | 853 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 681 | 0.070 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 58 | 0.070 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 642 | 0.070 |
Why?
| | Biopsy | 2 | 2005 | 1079 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 2 | 2006 | 509 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 129 | 0.060 |
Why?
| | Radioisotopes | 1 | 2004 | 34 | 0.060 |
Why?
| | Biomarkers, Tumor | 1 | 2011 | 1059 | 0.060 |
Why?
| | Genetic Linkage | 1 | 2005 | 321 | 0.060 |
Why?
| | Radiation Dosage | 1 | 2005 | 147 | 0.060 |
Why?
| | Exercise | 1 | 2015 | 1657 | 0.060 |
Why?
| | HLA-DRB3 Chains | 1 | 2003 | 2 | 0.060 |
Why?
| | HLA-DRB5 Chains | 1 | 2003 | 2 | 0.060 |
Why?
| | HLA-DRB4 Chains | 1 | 2003 | 6 | 0.060 |
Why?
| | fas Receptor | 1 | 2004 | 98 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2014 | 9342 | 0.060 |
Why?
| | Phagocytes | 1 | 2004 | 91 | 0.060 |
Why?
| | Antioxidants | 1 | 2008 | 564 | 0.060 |
Why?
| | HLA-DQ beta-Chains | 1 | 2003 | 61 | 0.060 |
Why?
| | CD28 Antigens | 1 | 2003 | 46 | 0.060 |
Why?
| | Tuberculosis | 1 | 2006 | 240 | 0.060 |
Why?
| | Odds Ratio | 3 | 2014 | 996 | 0.060 |
Why?
| | Public Health | 2 | 2022 | 450 | 0.060 |
Why?
| | Animals, Laboratory | 1 | 2003 | 13 | 0.060 |
Why?
| | Immunologic Tests | 1 | 2003 | 16 | 0.060 |
Why?
| | Chi-Square Distribution | 1 | 2004 | 525 | 0.060 |
Why?
| | Physiological Phenomena | 1 | 2002 | 1 | 0.060 |
Why?
| | Kinetics | 1 | 2006 | 1624 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 870 | 0.060 |
Why?
| | Disposable Equipment | 1 | 2002 | 15 | 0.060 |
Why?
| | Contraindications | 1 | 2002 | 86 | 0.050 |
Why?
| | NF-kappa B | 1 | 2006 | 670 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 1 | 2002 | 124 | 0.050 |
Why?
| | Genetic Variation | 1 | 2007 | 926 | 0.050 |
Why?
| | Patch Tests | 1 | 2002 | 50 | 0.050 |
Why?
| | Nuclear Proteins | 1 | 2006 | 597 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2002 | 88 | 0.050 |
Why?
| | Oxygen Consumption | 1 | 2004 | 586 | 0.050 |
Why?
| | Epitopes | 1 | 2003 | 443 | 0.050 |
Why?
| | Nuclear Weapons | 2 | 2011 | 7 | 0.050 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 151 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 827 | 0.050 |
Why?
| | Equipment Design | 1 | 2002 | 519 | 0.050 |
Why?
| | Exercise Test | 1 | 2003 | 551 | 0.050 |
Why?
| | Radiography | 1 | 2003 | 861 | 0.050 |
Why?
| | ROC Curve | 2 | 2003 | 473 | 0.050 |
Why?
| | Hearing Loss, Noise-Induced | 1 | 2019 | 16 | 0.050 |
Why?
| | 2,4-Dinitrophenol | 1 | 2019 | 10 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 1945 | 0.040 |
Why?
| | Kidney Medulla | 1 | 2019 | 32 | 0.040 |
Why?
| | Infliximab | 2 | 2012 | 94 | 0.040 |
Why?
| | Quality of Life | 2 | 2012 | 2366 | 0.040 |
Why?
| | Amino Acid Sequence | 4 | 2009 | 2071 | 0.040 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2019 | 74 | 0.040 |
Why?
| | Acute Disease | 1 | 2002 | 940 | 0.040 |
Why?
| | Selection Bias | 1 | 2018 | 35 | 0.040 |
Why?
| | Organizational Case Studies | 1 | 2018 | 74 | 0.040 |
Why?
| | Molecular Sequence Data | 4 | 2009 | 2871 | 0.040 |
Why?
| | Cities | 1 | 2018 | 96 | 0.040 |
Why?
| | Transcription Factors | 1 | 2006 | 1570 | 0.040 |
Why?
| | Health | 1 | 2018 | 81 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2011 | 2220 | 0.040 |
Why?
| | Genetic Association Studies | 2 | 2010 | 371 | 0.040 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1012 | 0.040 |
Why?
| | Fibrosis | 1 | 2000 | 483 | 0.040 |
Why?
| | Haplotypes | 2 | 2010 | 473 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2018 | 204 | 0.040 |
Why?
| | Cost of Illness | 1 | 2018 | 258 | 0.040 |
Why?
| | Histocompatibility Testing | 2 | 2009 | 123 | 0.040 |
Why?
| | Observer Variation | 1 | 1997 | 309 | 0.040 |
Why?
| | Administration, Oral | 1 | 2018 | 756 | 0.040 |
Why?
| | Sanitation | 1 | 2016 | 52 | 0.030 |
Why?
| | Community Health Nursing | 1 | 2016 | 63 | 0.030 |
Why?
| | Poverty | 1 | 2019 | 444 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4596 | 0.030 |
Why?
| | Gene Frequency | 2 | 2010 | 513 | 0.030 |
Why?
| | Antibody Formation | 1 | 1997 | 276 | 0.030 |
Why?
| | Antigens | 1 | 1997 | 320 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2012 | 1687 | 0.030 |
Why?
| | Community Participation | 1 | 2016 | 120 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2002 | 310 | 0.030 |
Why?
| | Education, Nursing | 1 | 2016 | 79 | 0.030 |
Why?
| | Siblings | 2 | 2006 | 235 | 0.030 |
Why?
| | Universities | 1 | 2016 | 347 | 0.030 |
Why?
| | Qualitative Research | 1 | 2018 | 953 | 0.030 |
Why?
| | Asthma | 2 | 2019 | 2158 | 0.030 |
Why?
| | Mitochondria | 1 | 2019 | 786 | 0.030 |
Why?
| | Disease Susceptibility | 2 | 2000 | 331 | 0.030 |
Why?
| | Cleft Palate | 1 | 2014 | 48 | 0.030 |
Why?
| | Infant, Low Birth Weight | 1 | 2014 | 125 | 0.030 |
Why?
| | Neural Tube Defects | 1 | 2014 | 63 | 0.030 |
Why?
| | Dyspnea | 2 | 2005 | 201 | 0.030 |
Why?
| | Interleukin-2 | 2 | 2005 | 416 | 0.030 |
Why?
| | Education, Medical | 1 | 2016 | 239 | 0.030 |
Why?
| | Lung Diseases | 1 | 1999 | 718 | 0.030 |
Why?
| | Politics | 1 | 2013 | 80 | 0.030 |
Why?
| | Maternal Exposure | 1 | 2014 | 142 | 0.030 |
Why?
| | Pregnancy | 2 | 2014 | 5691 | 0.030 |
Why?
| | Epidemiological Monitoring | 1 | 2012 | 49 | 0.030 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2011 | 33 | 0.030 |
Why?
| | Pneumonia | 1 | 1997 | 592 | 0.030 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2002 | 19 | 0.020 |
Why?
| | Inflammation | 1 | 2002 | 2566 | 0.020 |
Why?
| | Finland | 1 | 2011 | 71 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 410 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2012 | 270 | 0.020 |
Why?
| | Netherlands | 1 | 2010 | 62 | 0.020 |
Why?
| | Hazardous Substances | 1 | 2010 | 12 | 0.020 |
Why?
| | Japan | 1 | 2010 | 97 | 0.020 |
Why?
| | Premature Birth | 1 | 2014 | 284 | 0.020 |
Why?
| | Toxoplasma | 1 | 2010 | 34 | 0.020 |
Why?
| | United Kingdom | 1 | 2010 | 236 | 0.020 |
Why?
| | Salmonella enterica | 1 | 2010 | 53 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 1989 | 50 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 2009 | 156 | 0.020 |
Why?
| | HLA-B Antigens | 1 | 1989 | 55 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2005 | 1868 | 0.020 |
Why?
| | Demography | 1 | 2009 | 274 | 0.020 |
Why?
| | Halogens | 1 | 2007 | 13 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 1974 | 0.020 |
Why?
| | Codon | 1 | 2007 | 89 | 0.020 |
Why?
| | Tuberculin | 1 | 2006 | 6 | 0.020 |
Why?
| | Heart Defects, Congenital | 1 | 2014 | 703 | 0.020 |
Why?
| | Disinfection | 1 | 2007 | 108 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2009 | 300 | 0.020 |
Why?
| | Placebos | 1 | 2006 | 202 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1047 | 0.020 |
Why?
| | Decision Making | 1 | 2013 | 809 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 305 | 0.020 |
Why?
| | Eye | 1 | 2006 | 106 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2009 | 1085 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2007 | 481 | 0.020 |
Why?
| | Caspase 8 | 1 | 2005 | 47 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2005 | 136 | 0.020 |
Why?
| | Genetic Techniques | 1 | 2005 | 60 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2005 | 88 | 0.020 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 381 | 0.020 |
Why?
| | Metalloporphyrins | 1 | 2005 | 103 | 0.020 |
Why?
| | Adenocarcinoma | 1 | 2011 | 812 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2005 | 510 | 0.020 |
Why?
| | Caspases | 1 | 2005 | 269 | 0.010 |
Why?
| | Species Specificity | 1 | 2005 | 565 | 0.010 |
Why?
| | Abatacept | 1 | 2003 | 42 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 266 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1323 | 0.010 |
Why?
| | Radioallergosorbent Test | 1 | 2003 | 4 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2003 | 82 | 0.010 |
Why?
| | Thymidine | 1 | 2003 | 62 | 0.010 |
Why?
| | Geography | 1 | 2003 | 190 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2014 | 5255 | 0.010 |
Why?
| | Skin Tests | 1 | 2003 | 135 | 0.010 |
Why?
| | Genetic Testing | 1 | 2005 | 389 | 0.010 |
Why?
| | Immunoconjugates | 1 | 2003 | 89 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2003 | 307 | 0.010 |
Why?
| | Mice, Inbred A | 1 | 2001 | 45 | 0.010 |
Why?
| | Autoantibodies | 1 | 1989 | 1335 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 190 | 0.010 |
Why?
| | Ceramics | 1 | 2001 | 19 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2008 | 1178 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 250 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2001 | 336 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 372 | 0.010 |
Why?
| | Dogs | 1 | 2001 | 371 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1999 | 26 | 0.010 |
Why?
| | Models, Animal | 1 | 2001 | 363 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 353 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 248 | 0.010 |
Why?
| | Models, Statistical | 1 | 2003 | 636 | 0.010 |
Why?
| | Liver | 1 | 2006 | 1816 | 0.010 |
Why?
| | Cell Movement | 1 | 2002 | 896 | 0.010 |
Why?
| | Skin | 1 | 2002 | 657 | 0.010 |
Why?
| | Depression | 1 | 2005 | 1132 | 0.010 |
Why?
| | Models, Molecular | 1 | 2001 | 1435 | 0.010 |
Why?
| | Bronchography | 1 | 1993 | 10 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2005 | 4708 | 0.010 |
Why?
| | Bronchiectasis | 1 | 1993 | 105 | 0.010 |
Why?
|
|
Newman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|